Phase IIa trial of a fixed-dose combination of leucine, metformin and a PDE5 inhibitor

Trial Profile

Phase IIa trial of a fixed-dose combination of leucine, metformin and a PDE5 inhibitor

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2015

At a glance

  • Drugs Leucine (Primary) ; Metformin; Sildenafil
  • Indications Non-alcoholic fatty liver disease
  • Focus Therapeutic Use
  • Sponsors NuSirt Biopharma
  • Most Recent Events

    • 09 Jun 2015 New trial record
    • 06 Jun 2015 Initiation of this trial is planned later in 2015, according to a NuSirt Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top